Phase II Trial of Systemic Recombinant Interleukin-2 in the Treatment of Refractory Nasopharyngeal Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|60|2|110-115

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.2, 2001-02, pp. : 110-115

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Surgical Resection of Metastases Refractory to Systemic Therapy on Survival and Quality of Life – a Phase II Trial

By  

Oncology Research and Treatment, Vol. 22, Iss. 6, 2000-01 ,pp. : 486-489

Karger

Access to resources Recommend Favorite

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 5, 2015-05 ,pp. : 722-726

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 223-228

Karger

Access to resources Recommend Favorite

Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 174, Iss. 6, 2016-09 ,pp. : 859-867

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 343-346

Karger

Access to resources Recommend Favorite